Mycophenolate mofetil inhibits Merkel cell carcinoma growth.

Br J Dermatol

Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD.

Published: March 2024

The direct antitumour effects of mTOR inhibitors against cutaneous squamous cell carcinoma (SCC) have prompted a paradigm shift towards using sirolimus for allograft rejection prophylaxis in patients with high-risk SCC who have had a solid organ transplant (SOT). Patients who have had an SOT are at higher risk for Merkel cell carcinoma (MCC), yet there is little evidence concerning potential antitumour effects of immunosuppressive drugs against MCC. Screening seven immunosuppressive drugs in six MCC cell lines revealed that mycophenolate mofetil (MMF) had strong antitumour activity (surpassing mTOR inhibitors) and higher potency in MCC vs. other cancer types. MMF also inhibited MCC tumour growth in mice. Our preclinical findings strongly suggest the utility of MMF in patients with MCC who require immunosuppression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941324PMC
http://dx.doi.org/10.1093/bjd/ljae018DOI Listing

Publication Analysis

Top Keywords

cell carcinoma
12
mycophenolate mofetil
8
merkel cell
8
antitumour effects
8
mtor inhibitors
8
immunosuppressive drugs
8
drugs mcc
8
mcc
6
mofetil inhibits
4
inhibits merkel
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!